{
  "id": 19413520,
  "title": "Inovio Q3 2026 slides: VOCERYQ approval amid wider loss",
  "url": "https://urgent.news/2026/11/10/inovio-q3-2026-slides-voceryq-approval-amid-wider-loss",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-10T23:21:17.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/inovio-q3-2026-slides-voceryq-approval-amid-wider-loss-93CH-5017309"
  },
  "original_language": "en",
  "account": "Inovio Pharmaceuticals disclosed its third-quarter 2026 financials on November 10, 2026, signaling a shift to commercial-stage biotech following FDA approval of VOCERYQ™, the first plasmid DNA immunotherapy in the U.S. Despite this milestone, the company reported a wider-than-expected loss of $49.2 million, or $0.50 per share, compared to analyst projections of a $0.21 loss, or $0.21 per share. Shares fell 3.97% to $1.45 in regular trading and an additional 10.34% after hours to $1.3001. The per-share loss narrowed from $0.87 a year ago, but the miss highlighted investor concerns over the company's cost structure and execution risks during commercialization. Operating expenses saw a 7% year-over-year decline to $19.8 million, and a 13% decrease to $60.4 million on a nine-month basis. However, the net loss for the quarter improved by 16% to $49.2 million, or $0.50 per share, compared to $45.5 million a year earlier, mainly due to a $26.9 million non-cash loss on warrant liabilities. Inovio reported $48.4 million in cash, cash equivalents, and short-term investments without any debt. The company's key product, VOCERYQ™, received FDA approval under an accelerated pathway for reducing surgery frequency in adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV types 6 and 11. The approval is contingent on verification of clinical benefits in confirmatory studies set to begin following FDA alignment expected by mid-2027. VOCERYQ™ demonstrated a 50-100% reduction in surgeries, with 28% of patients achieving complete response and 50% in Year 2. Adverse reactions were generally mild to moderate, with injection site reactions and headache being the most common. The U.S. RRP patient population is estimated at over 25,000 adults, with most managed surgically. Inovio plans to target 400 laryngologists treating the majority of these patients, leveraging a concentrated field footprint to launch VOCERYQ™ by late fourth quarter 2027, barring anticipated revenue.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}